This company has shut down. Ikena Oncology is no longer operating — its last tracked round was a Post-IPO Equity in 2023.
Explore the Startup GraveyardIkena Oncology develops differentiated therapies to target cancer growth and resistance, focusing on Hippo and RAS signaling pathways.
Ikena Oncology has raised $40.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2023.
Ikena Oncology's investors include Fidelity, OrbiMed, Atlas Venture, Invus, Bristol-Myers Squibb.
Ikena Oncology is headquartered in Boston, United States.
Ikena Oncology develops differentiated therapies to target cancer growth and resistance, focusing on Hippo and RAS signaling pathways.
Ikena Oncology is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ikena Oncology — Funding & Investors." VCBacked, May 15, 2023, https://www.vcbacked.co/company/ikena-oncology. Accessed August 14, 2026.
VCBacked. (2023). Ikena Oncology — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/ikena-oncology
{{cite web |title=Ikena Oncology — Funding & Investors |url=https://www.vcbacked.co/company/ikena-oncology |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated